Target intelligence / Profile preview

Rotavirus structural proteins (VP)

Target
VP
Molecular classification
Structural viral protein, Capsid protein, Virus particle protein, Antigen (for immunological context), Other
01

Overview

Rotavirus structural proteins are components of the rotavirus virion essential for its architecture, infectivity, and replicative cycle. The major structural proteins include VP1 (RNA-dependent RNA polymerase), VP2 (core shell), VP3 (guanylyltransferase/methyltransferase), VP4 (spike protein mediating cell attachment/entry), VP6 (forms the intermediate capsid layer), and VP7 (outer capsid glycoprotein). These proteins form three concentric layers that encapsulate the virus's 11-segment double-stranded RNA genome. VP4 and VP7 are the main antigens recognized by neutralizing antibodies, making them targets for current vaccines, and the VP6 protein is commonly used as a biomarker for laboratory diagnosis. The collective term "rotavirus structural proteins" is a functional grouping; each protein has a distinct sequence, role, and relevance in infection, diagnostics, or immunology. There are currently no direct small-molecule therapeutics targeting these proteins; intervention is mainly via vaccine-elicited immunity.

Other names
Viral protein (VP)Rotavirus capsid proteinRotavirus virion protein
02

Mechanism of action

Neutralizing antibody: blocks viral attachment or penetration (for VP4, VP7); Vaccine-mediated immunity

03

Biological functions

Virion structural integrityCell entryHost cell attachment (e.g., VP4, VP7)Genome encapsidation and protectionEssential for endogenous viral transcription (e.g., VP1, VP2)Eliciting immune response
04

Disease associations

Infection (rotavirus gastroenteritis)Other (primary role in viral infectivity/pathogenic process)
05

Safety considerations

Vaccine safety concerns may include intussusception (rotavirus vaccine specific, not the proteins per se)Immune escape by antigenic drift/shift in VP7/VP4No significant direct toxicity associated with the protein targets, but immune hypersensitivity to viral antigens is theoretically possible
06

Interacting drugs

None approved as direct-acting drugs targeting structural proteins

2 more in the full profile.

07

Biomarkers

VP6 antigen (primary diagnostic marker in clinical assays)Presence of VP7/VP4 (used in epidemiological subtyping/G, P genotyping)

Beyond the preview

Go deeper on Rotavirus structural proteins (VP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rotavirus structural proteins (VP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call